If you have been reading about afamelanotide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
=== Magnetic plasmon resonance === Recently, there has been an interest in magnetic surface plasmons. These require materials with large negative magnetic permeability, a property that has only recently been made available with the construction of metamaterials.
=== September === 1 September – John Swinney gives his keynote speech to the SNP Annual Conference, saying that he will put the "people's priorities" at the heard of the Scottish Government, and that he will work to convince voters that Scottish independence is the "route" to delivering a fairer and stronger country. 2 September – The Scottish Government confirms that all young offenders under the age of 18 have been removed from Scotland's young offenders' institutions and transferred to more child-friendly accommodation. 3 September – In a statement to the Scottish Parliament, Finance Secretary Shona Robison outlines £500m of spending cuts. She argues the cuts are needed because of an additional £800m in financial costs brought about by public sector pay deals, austerity from Westminster, inflation, the COVID-19 pandemic and the Russian invasion of Ukraine. BBC News reports that the headquarters of GB Energy, the new government-backed energy company, will be in Aberdeen. Members of the Unison trade union working for councils in Scotland reject an annual pay increase offer worth 3.6%, equivalent to at least £1,292. 4 September – The Scottish Government abandons an unfulfilled commitment to expand free school meals to all primary school pupils. 5 September – Scottish rugby player Scott Hastings confirms his wife, Jenny Hastings, has been reported missing after disappearing at a location used for wild swimming in the Firth of Forth on 3 September.
Deep fascia is a layer of dense fibrous connective tissue which surrounds individual muscles and divides groups of muscles into fascial compartments. This fascia has a high density of elastin fibre that determines its extensibility or resilience. Deep fascia was originally considered to be essentially avascular but later investigations have confirmed a rich presence of thin blood vessels. Deep fascia is also richly supplied with sensory receptors. Histologically, fascia is composed predominantly of type I collagen fibers with variable amounts of elastin, which together determine tensile strength and extensibility. Fibroblasts are the principal resident cells, and fascial tissue contains vascular elements (particularly in deep fascia), immune cells such as macrophages and mast cells, and a dense array of sensory nerve endings; these features enable fascia to participate in repair, inflammation, and nociception. Examples of deep fascia are fascia lata, fascia cruris, brachial fascia, plantar fascia, thoracolumbar fascia and Buck's fascia.
== Treatment == CTD is difficult to treat because the transporter responsible for transporting creatine to the brain and muscles is defective. Affected individuals have sufficient amounts of creatine, but it cannot get to the tissues where it is needed. Studies in which oral creatine monohydrate supplements were given to patients with CTD found that patients did not respond to treatment. Patients with CTD are unresponsive to oral creatine monohydrate supplements because regardless of the amount of creatine they ingest, the creatine transporter is still defective, and therefore creatine is incapable of being transported across the BBB. Therapeutic approaches that are currently in development include dodecyl creatine ester (DCE) for intranasal creatine delivery, pharmacochaperones to aid in rescuing misfolded transporter, and gene therapy to compensate for the mutated SLC6A8 gene.
By 13 June 1917, it was acknowledged by Ronald Graham, head of the Foreign Office's Middle Eastern affairs department, that the three most relevant politicians – the Prime Minister, the Foreign Secretary, and the Parliamentary Under-Secretary of State for Foreign Affairs, Lord Robert Cecil – were all in favour of Britain supporting the Zionist movement; on the same day Weizmann had written to Graham to advocate for a public declaration. Six days later, at a meeting on 19 June, Balfour asked Lord Rothschild and Weizmann to submit a formula for a declaration. Over the next few weeks, a 143-word draft was prepared by the Zionist negotiating committee, but it was considered too specific on sensitive areas by Sykes, Graham and Rothschild. Separately, a very different draft had been prepared by the Foreign Office, described in 1961 by Harold Nicolson – who had been involved in preparing the draft – as proposing a "sanctuary for Jewish victims of persecution". The Foreign Office draft was strongly opposed by the Zionists, and was discarded; no copy of the draft has been found in the Foreign Office archives. Following further discussion, a revised – and at just 46 words in length, much shorter – draft declaration was prepared and sent by Lord Rothschild to Balfour on 18 July. It was received by the Foreign Office, and the matter was brought to the Cabinet for formal consideration.
Sources: en.wikipedia.org
== Membrane-associated transferases == Many transferases associate with biological membranes as peripheral membrane proteins or anchored to membranes through a single transmembrane helix, for example numerous glycosyltransferases in Golgi apparatus. Some others are multi-span transmembrane proteins, for example certain oligosaccharyltransferases or microsomal glutathione S-transferase from MAPEG family.
"God knows it did not cross our minds to attack the towers, but after [witnessing] [...] the destroyed towers in Lebanon, it occurred to me [to] punish the unjust the same way: to destroy towers in America, so it could taste some of what we are tasting, and to stop killing our children and women." Other motives have been suggested in addition to those stated by him and other al-Qaeda members. Some authors suggested the "humiliation" that resulted from the Islamic world falling behind the Western world—this discrepancy was rendered especially visible by globalization—as well as a desire to provoke the U.S. into a broader war against the Islamic world in the hope of motivating more allies to support al-Qaeda. Similarly, others have argued the 9/11 attacks were a strategic move to provoke America into a war that would incite a pan-Islamic revolution.
==== Standard products ==== Non-exclusives, "standard" or "catalogue products" constitute the second most important outlet for fine chemicals after custom manufacturing. API-for-Generics are the most important sub-category. Because of patent expiries, over 60 of the top 200 drugs alone, representing aggregated sales of over $150 billion, have fallen into the public domain within the past decade. This, along with government-backed incentives, are causing global sales of generics to rapidly increase. Asian companies currently dominate the API-for-Generics business. They have multiple advantages, including their low cost basis, large home markets, and significant previous manufacturing experience compared to western manufacturers in producing for their domestic and other non-regulated markets.
==== Elimination ==== Gabapentin, pregabalin, Baclofen and phenibut are all eliminated renally in the urine. They all have relatively short elimination half-lives, with reported values of 5.0 to 7.0 hours, 6.3 hours, 2.0 to 5.0 hours and 5.3 hours, respectively. Similarly, the terminal half-life of gabapentin enacarbil IR (as active gabapentin) is short at approximately 4.5 to 6.5 hours. Because of its short elimination half-life, gabapentin must be administered 3 to 4 times per day to maintain therapeutic levels. Similarly, pregabalin has been given 2 to 3 times per day in clinical studies. Phenibut, also, is taken 3 times per day. Conversely, gabapentin enacarbil is taken twice a day and gabapentin XR (brand name Gralise) is taken once a day.
Sources: en.wikipedia.org
In a $3.3 million project funded through Genome Canada's Genomic Applications Partnership Program, Borchers and Gerald Batist developed an automated iMALDI assay quantifying the protein kinases Akt1 and Akt2, with AstraZeneca as the industry partner.
In 2007, Waffle House repurchased the original restaurant, which had been sold by the chain in the early 1970s. The company restored it using original blueprints for use as a private company museum. The museum is used primarily for internal corporate events and tours. In 2008, one of the biggest Waffle House franchises in the southeast, North Lake Foods, was bought out by Waffle House, Inc. North Lake Foods filed for Chapter 11 bankruptcy protection and closed some stores. Waffle House, Inc. plans to rehabilitate the franchise. In early 2009, East Coast Waffles bought North Lake Foods to become a new franchise. The founders of the Waffle House brand died in 2017 within two months of each other: Joe Rogers Sr. died on March 3 and Tom Forkner on April 26. On September 8, 2024, it was reported that Walter G. Ehmer, who oversaw Waffle House since 2012, had died. In 2025, Waffle House introduced canned cold brew as a new "all-star" to its lineup as a limited run in nine locations, all of which are in Atlanta.
== Side effects == The adverse effects include drowsiness, dizziness, confusion, constipation, anxiety, nausea, blurred vision, restlessness, decreased coordination, dry mouth, shallow breathing, hallucinations, irritability, problems with memory or concentration, tinnitus and trouble urinating. Chlorphenamine produces less sedation than other first-generation antihistamines. A large study on people 65 years old or older linked the development of Alzheimer's disease and other forms of dementia to the "higher cumulative" use of chlorphenamine and other first-generation antihistamines, due to their anticholinergic properties. Chlorphenamine is rated as a "high burden" anticholinergic by experts on a semi-subjective scale. This is inconsistent with the in vitro experiments showing low affinity to muscarinic acetylcholine receptors (see below).
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.